EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lytic Epstein-Barr virus infection and emerging autoantibodies precede multiple sclerosis prodrome

Viktor Grut iD, Jens Ingvarsson iD, Martin Biström, Daniel Jons iD, Birgitta E Michels, Julia Butt iD, Tim Waterboer iD, Tomas Bergström, Staffan Nilsson, Olivia G Thomas, Tomas Olsson, Peter Sundström

Brain · 22.08.2026

DOI: 10.1093/brain/awag283 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 22.08.2026. Verfasst von Viktor Grut und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Neurosciences, Umeå University, 90187 Umeå, Sweden. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epstein-Barr virus (EBV) is a critical risk factor for multiple sclerosis (MS), but the pathogenic mechanisms remain elusive. To clarify its role in MS, we examined the sequence of EBV-related antibody responses over a broad period before the clinical onset of MS, from early childhood to middle age. A nested case-control study was performed by linking Swedish MS registries with biobanks to identify pre-symptomatic samples from individuals who later developed MS and matched controls. Leveraging these samples, we analysed the immune responses to EBV in and before the prodromal phase of MS. Antibodies against EBV (viral capsid antigen, VCA; EBV nuclear antigen 1, EBNA1; early antigen-diffuse, EA-D) and the putative autoantibody target Anoctamin 2 (ANO2) were quantified by immunoassay. Serum neurofilament light chain (S-NfL), a marker of axonal injury, was quantified by single-molecule array. Ratios of these markers were calculated within each matched case-control set, plotted against time to the clinical onset of MS, and analysed with Loess regression to visualise the temporal order of events on group level. Samples from 981 cases and 1278 controls were included. Median age at blood sampling was 22 years and 32% of the participants were children or adolescents. The median time from the blood sample to the clinical onset of MS was 9 years. On the group level, we observed the following sequence of events: Seroreactivity against lytic EBV antigens (VCA-IgG, VCA-IgM, EA-D) – characterizing primary EBV infection and reactivation – were significantly higher in cases than in controls more than 20 years before MS onset and onwards. Increased seroreactivity against the latent antigen EBNA1 was observed 15 years before onset, followed by increased ANO2 seroreactivity from 9 years and onwards. Finally, a significant elevation of S-NfL was observed from 7 years prior to MS onset. These findings demonstrate a more extensive lytic EBV infection in the decades before MS onset, consistent with the hypothesis that EBV is a driver of MS development. The sequence of increasing seroreactivity against EBNA1 and ANO2 was closely followed by biochemical signs of neuroaxonal injury, suggesting epitope spreading from EBNA1 before the subclinical onset of neuroaxonal damage. This sequence of events supports the hypothesis that EBV infection promotes autoreactive immune cells contributing to MS pathogenesis.

Schlagwörter

Stichwörter der Autor:innen

Epstein-Barr virusmultiple sclerosisserology

Autor:innen und Institutionen

  • Department of Clinical Sciences, Neurosciences, Umeå University, 90187 Umeå, Sweden.
  • Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, 40530 Gothenburg, Sweden.
  • Division of Infections and Cancer Epidemiology, German Cancer Research Center, 69120 Heidelberg, Germany.
  • Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, 40530 Gothenburg, Sweden.
  • Department of Clinical Microbiology, Sahlgrenska University Hospital, 40530 Gothenburg, Sweden.
  • Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.

ORCID-Profile: Viktor Grut, Jens Ingvarsson, Daniel Jons, Julia Butt, Tim Waterboer

Zitieren

APA

Grut, V., Ingvarsson, J., Biström, M., Jons, D., Michels, B. E., Butt, J., Waterboer, T., Bergström, T., Nilsson, S., Thomas, O. G., Olsson, T., & Sundström, P. (2026). Lytic Epstein-Barr virus infection and emerging autoantibodies precede multiple sclerosis prodrome. Brain. https://doi.org/10.1093/brain/awag283

Vancouver

Grut V, Ingvarsson J, Biström M, Jons D, Michels BE, Butt J, et al. Lytic Epstein-Barr virus infection and emerging autoantibodies precede multiple sclerosis prodrome. Brain. 2026. doi:10.1093/brain/awag283

BibTeX
@article{Grut2026,
  author = {Grut, Viktor and Ingvarsson, Jens and Biström, Martin and Jons, Daniel and Michels, Birgitta E and Butt, Julia and Waterboer, Tim and Bergström, Tomas and Nilsson, Staffan and Thomas, Olivia G and Olsson, Tomas and Sundström, Peter},
  title = {Lytic Epstein-Barr virus infection and emerging autoantibodies precede multiple sclerosis prodrome},
  journal = {Brain},
  year = {2026},
  doi = {10.1093/brain/awag283}
}
Kostenlos starten →